BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
Volume: 43, Pages: 102186 - 102186
Published: Aug 1, 2020
Abstract
ObjectivesOcrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows high intra and inter-individual variability. The aim of this study was to explore the influence of Body Mass Index (BMI) on kinetic of B-cell repopulation after treatment with OCR and on treatment response.Methods108 Multiple Sclerosis (MS) patients were enrolled at the...
Paper Details
Title
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
Published Date
Aug 1, 2020
Volume
43
Pages
102186 - 102186
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History